Camrelizumab Combined With Apatinib Mesylate

Sponsor
Henan Cancer Hospital
Study ID
NCT05380986
Status
Unknown

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab combined with apatinib mesylate — DRUG
    Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Study Details

The purpose of this study is to observe the safety of camrelizumab combined with apatinib mesylate in the treatment of solid tumors

Key Dates

Start date
May 20, 2022
Status verified
May 2022
Primary completion
May 1, 2024
Completion
May 1, 2025

Study Design

Enrollment
500 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab combined with apatinib mesylate
    Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Primary Outcome Measure

AE [ Time Frame: up to 2 years ]

Related Studies